Polar vectors as a method for evaluating the effectiveness of irritable bowel syndrome treatments: An analysis with pinaverium bromide 100mg plus simethicone 300mg po bid;Vectores polares como método para evaluar la eficacia de tratamientos para el síndrome de intestino irritable: Análisis con bromuro de pinaverio 100mg más simeticona 300mg po bid

Revista de Gastroenterologia de Mexico

Volumn 78, Issue 1, 2013, Pages 21-27

  Lopez Alvarenga J C ^a   Sobrino Cossio S ^b   Remes Troche, J M ^c   Chiu Ugalde, J ^a,d   Vargas Romero, J A ^e   Schmulson, M ^f  

^a HOSPITAL GENERAL DE MÉXICO   (Mexico)

^b INSTITUTO NACIONAL DE CANCEROLOGÍA   (Mexico)

^c UNIVERSIDAD VERACRUZANA   (Mexico)

^d Department of Clinical Studies ^*  (Mexico)

^e Medical Office   (Mexico)

^f UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

Author keywords

Bristol stool scale; Clinical studies; Irritable bowel syndrome; Outcome measures; Pinaverium bromide plus Simethicone; Polar vectors

Indexed keywords

EID: 84876391162     PISSN: 03750906     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rgmx.2012.10.003     Document Type: Article

References (13)

1. Longstreth GF, Thompson WG, Chey WD, et al. Functional bowel disorders. Gastroenterology. 2006;130:1480-91.
2. Drossman DA. The functional gastrointestinal disorders and the Rome III process. Gastroenterology. 2006;130:1377-90.
3. Chang L, Drossman DA. Rome Foundation Endpoints and Outcomes Conference 2009: Optimizing Clinical Trials in FGID. Am J Gastroenterol. 2010;105:722-30.
4. Trentacosti AM, He R, Burke LB, et al. Evolution of clinical trials for irritable bowel syndrome: issues in end points and study design. Am J Gastroenterol. 2010;105:731-5.
5. WMA Declaration of Helsinki - Ethical Principles for Medical Research Involving Human Subjects [Internet]. World Medical Association; 2008. http://www.wma.net/en/30publications/10policies/b3/index.html [cited on 29.09.10].
6. International Conference on Harmonization of Technical Requirements for the Registration of Pharmaceuticals for Human Use. ICH Harmonised Tripartite Guideline. Guideline for Good Clinical Practice E6 (R1); 10 June 1996. Available from: http://www.ich.org/fileadmin/Public Web Site/ICH Products/Guidelines/ Efficacy/E6 R1/Step4/E6 R1 Guideline.pdf
7. Camilleri M, Chang L. Challenges to the therapeutic pipeline for irritable bowel syndrome: end points and regulatory hurdles. Gastroenterology. 2008;135:1877-91.
8. Spiller RC. Potential biomarkers. Gastroenterol Clin North Am. 2011;40:121-39;
9. Barbara G, Stanghellini V. Biomarkers in IBS: when will they replace symptoms for diagnosis and management? Gut. 2009;58:1571-5.
10. Spiegel B, Bolus R, Harris LA, et al. Measuring irritable bowel syndrome patient-reported outcomes with an abdominal pain numeric rating scale. Aliment Pharmacol Ther. 2009;30:1159-70.
11. Drossman DA. Functional versus organic: an inappropriate dichotomy for clinical care. Am J Gastroenterol. 2006;101:1172-5.
12. Spiegel BM, Bolus R, Agarwal N, et al. Measuring symptoms in the irritable bowel syndrome: development of a framework for clinical trials. Aliment Pharmacol Ther. 2010;32:1275-91.
13. Schmulson M, Jiménez A, Crespo Y, et al. Abdominal pain and anxiety are linked factors that affect the quality of life of patients with IBS. Neurogastroenterol Motil. 2011;29 Suppl. 1:11.